BTIG analyst Julien Harrison downgraded VYNE Therapeutics (VYNE) to Neutral from Buy with no price target after the company’s Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The full data set will be further analyzed to inform results and strategic next steps, while the management intends to seek a development and commercialization partner for repibresib and plans to provide an update on repibresib and VYN202, which is currently on partial clinical hold by the FDA, plans in the coming weeks, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics: Buy Rating Supported by Promising VYN202 Prospects Amidst Challenges
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- VYNE Therapeutics downgraded at H.C. Wainwright after vitiligo trial miss
- VYNE Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?